FIELD: medicine.
SUBSTANCE: claimed are pharmaceutical composition, which contains therapeutically efficient amount of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in form of pharmaceutically acceptable salt for treatment of progressing dementia or degenerative brain diseases and corresponding method of treatment. Demonstrated is inhibition by compound of monocyte chemotaxis, caused by β-amyloid protein in addition to agonistic activity to SIP receptor.
EFFECT: improvement of memory condition in patients with Alzheimer's disease.
7 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COURSE OF TREATMENT WITH APPLICATION OF RECEPTOR S1P AGONIST | 2005 |
|
RU2478384C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
| ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
| USING SIP RECEPTOR MODULATOR | 2008 |
|
RU2498796C2 |
| APPLICATION OF S1P RECEPTOR AGONIST AND METHOD OF TREATMENT, ALLEVIATION OR RETARDATION OF OPTIC NEURITIS OR DEMYELINATING DISEASES PROGRESSION | 2003 |
|
RU2391094C2 |
| COMPOSITIONS CONTAINING MODULATORS OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR | 2008 |
|
RU2779056C2 |
| ORGANIC COMPOUNDS | 2003 |
|
RU2478378C2 |
| LIQUID COMPOSITIONS | 2006 |
|
RU2428180C2 |
| MODULATORS OF RECEPTOR S1P FOR TREATMENT OF MULTIPLE SCLEROSIS | 2007 |
|
RU2569732C9 |
